NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CKPT

Checkpoint Therapeutics Inc

Apr 17 • 04:00PM ET

4.04

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: MRK JNJ PFE NVS VRTX AMGN GILD BPMC INCY EXEL

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	25.93%	Shs Outstand	83.76M	Perf Week	1.76%
Market Cap	351.56M	Forward P/E	3.58	EPS next Y	1.13	Insider Trans	-5.28%	Shs Float	64.48M	Perf Month	-0.74%
Income	-56.24M	PEG	-	EPS next Q	-0.10	Inst Own	24.09%	Short Float	7.80%	Perf Quarter	21.32%
Sales	0.04M	P/S	8789.00	EPS this Y	82.04%	Inst Trans	12.58%	Short Ratio	1.90	Perf Half Y	53.03%
Book/sh	-0.23	P/B	-	EPS next Y	543.14%	ROA	-875.40%	Short Interest	5.03M	Perf Year	139.05%
Cash/sh	0.08	P/C	53.27	EPS next 5Y	-	ROE	-	52W Range	1.38 - 4.50	Perf YTD	26.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.34%	ROI	-	52W High	-10.22%	Beta	1.14
Dividend TTM	-	Quick Ratio	0.37	Sales past 5Y	-49.45%	Gross Margin	-	52W Low	192.75%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	0.37	EPS Y/Y TTM	56.60%	Oper. Margin	-137009.76%	RSI (14)	63.60	Volatility	0.78% 0.91%
Employees	24	Debt/Eq	-	Sales Y/Y TTM	-60.19%	Profit Margin	-137170.73%	Recom	2.33	Target Price	4.33
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	24.14%	Payout	-	Rel Volume	0.22	Prev Close	4.04
Sales Surprise	-	EPS Surprise	-11.68%	Sales Q/Q	-100.00%	Earnings	Mar 28 BMO	Avg Volume	2.65M	Price	4.04
SMA20	0.40%	SMA50	12.72%	SMA200	31.45%	Trades		Volume	582,485	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-25	Initiated	D. Boral Capital	Buy	$9
Jul-14-22	Resumed	B. Riley Securities	Buy	$7
Jun-09-21	Initiated	B. Riley Securities	Buy	$18
Jan-20-21	Initiated	Cantor Fitzgerald	Overweight	$16
May-29-19	Initiated	Lake Street	Buy
Dec-08-17	Initiated	H.C. Wainwright	Buy	$11

Mar-31-25 04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Mar-10-25 11:08AM	India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details (Benzinga) +61.13%
06:46AM	Top India Drugmaker to Buy US-Based Checkpoint for $355 Million (Bloomberg)
05:30AM	Sun Pharma to acquire Checkpoint Therapeutics (Pharmaceutical Technology)
05:30AM	Loading…
05:30AM	Sun Pharma agrees to acquire Checkpoint Therapeutics (Pharmaceutical Technology)
Mar-09-25 11:13PM	Indias Sun Pharma to buy Checkpoint Therapeutics for $355 mln (Investing.com)
10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) +11.28%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire)
Dec-16-24 09:22AM	FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection (Benzinga) -7.63%
06:59AM	Novo builds up manufacturing; Pepgen Duchenne trial put on hold (BioPharma Dive)
Dec-13-24 06:15PM	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) (GlobeNewswire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire)
Nov-14-24 04:10PM	Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) -9.26%
04:30PM	Loading…
Nov-12-24 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) +8.15%
Sep-16-24 07:30AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 (GlobeNewswire)
Sep-04-24 08:00AM	Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-16-24 12:00PM	What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock (Zacks)
Aug-13-24 04:05PM	Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.80%
Aug-12-24 08:30AM	Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Jul-25-24 07:30AM	Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire) +7.04%
Jul-15-24 08:00AM	GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research (GlobeNewswire) +6.81%
Jul-02-24 08:00AM	Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab (GlobeNewswire)
Jun-24-24 07:30AM	Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission (GlobeNewswire) +15.56%
May-15-24 04:15PM	Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.20%
May-13-24 08:30AM	Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-10-24 01:52PM	CKPT Stock Earnings: Checkpoint Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:30AM	Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
04:05PM	Loading…
Mar-28-24 04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-22-24 02:52PM	CKPT Stock Earnings: Checkpoint Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:30AM	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-24 08:00AM	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors (GlobeNewswire)
Jan-29-24 08:00AM	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire) +18.45%
Jan-11-24 08:15AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
Dec-18-23 07:31AM	UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy (Reuters) -44.88%
07:09AM	US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy (Reuters)
07:00AM	U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer (GlobeNewswire)
Dec-11-23 12:26PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 (InvestorPlace)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.63%
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) -5.29%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-14-23 04:15PM	Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jul-31-23 08:00AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire) -16.45%
Jul-27-23 07:00AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire) -13.15%
Jun-28-23 08:00AM	Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing (GlobeNewswire)
May-23-23 08:30AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-21-23 10:03AM	3 Stocks With 1,000% Upside Potential (InvestorPlace)
May-15-23 04:15PM	Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) +8.02%
04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-02-23 08:37AM	Checkpoint Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-31-23 08:00AM	Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -32.84%
Mar-30-23 08:00PM	Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-02-23 07:00AM	Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Feb-21-23 08:00AM	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -7.82%
Jan-17-23 08:30AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) -8.16%
Jan-04-23 08:00AM	Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire) +8.47%
Jan-01-23 09:36AM	Individual investors in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) are its biggest bettors, and their bets paid off as stock gained 36% last week (Simply Wall St.)
Dec-15-22 08:00AM	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.01%
Dec-05-22 04:30PM	Checkpoint Therapeutics Announces Reverse Stock Split (GlobeNewswire) -9.50% -22.84%
Nov-08-22 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Sep-22-22 08:30AM	Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-08-22 08:15AM	Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-12-22 08:00AM	Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jun-30-22 10:19AM	We're Keeping An Eye On Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate (Simply Wall St.)
Jun-16-22 09:29AM	Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients (Benzinga)
07:30AM	Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jun-06-22 04:30PM	Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -8.28%
May-19-22 08:30AM	Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 08:30AM	Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency (GlobeNewswire) +17.43%
May-12-22 04:30PM	Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +11.86%
Apr-28-22 08:00AM	Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-04-22 08:15AM	Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities (GlobeNewswire)
Apr-01-22 08:30AM	Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 (GlobeNewswire)
Mar-31-22 07:10PM	Here's What Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Mar-28-22 07:30AM	Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-10-22 10:55AM	2 Strong Buy Penny Stocks With Over 300% Upside Potential (TipRanks) +13.77%
Jan-26-22 10:00AM	2 Biotech Stocks That Could Be 10-Baggers in 2022 (Motley Fool)
Jan-25-22 04:30PM	Checkpoint Therapeutics to Participate in the B. Riley Securities Virtual Oncology Conference (GlobeNewswire) +12.33%
11:04AM	Checkpoint Therapeutics' Cosibelimab Posts 47.4% ORR In Skin Cancer Patients (Benzinga)
10:06AM	Why Checkpoint Therapeutics Stock Is Heating Up Today (Motley Fool)
07:30AM	Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Dec-08-21 08:30AM	Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer (GlobeNewswire) +5.48%
Nov-04-21 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results (GlobeNewswire)
07:50AM	A Look At The Intrinsic Value Of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) (Simply Wall St.)
Sep-22-21 08:30AM	Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-09-21 08:30AM	Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-06-21 02:13AM	Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-05-21 04:30PM	Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-08-21 08:30AM	Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-09-21 06:01PM	Why Checkpoint Therapeutics Skyrocketed Today (Motley Fool) +19.17%
08:02AM	5 Top Stock Gainers for Wednesday: SPI Energy, Checkpoint Therapeutics (TheStreet.com)
05:49AM	Checkpoint Therapeutics Soars on B. Riley Buy Rating, $18 Price Target (TheStreet.com)
Jun-03-21 08:00AM	Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics (Benzinga)

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oliviero James F III	CEO, President and Director	Apr 02 '25	Sale	4.04	15,090	60,964	3,759,929	Apr 03 07:27 PM
GRAY WILLIAM GARRETT	Chief Financial Officer	Apr 01 '25	Sale	4.05	12,322	49,904	1,446,322	Apr 03 07:26 PM
Oliviero James F III	CEO, President and Director	Feb 10 '25	Sale	3.15	10,331	32,543	3,775,019	Feb 11 09:00 PM
Oliviero James F III	CEO, President and Director	Feb 07 '25	Sale	3.41	9,233	31,485	3,785,350	Feb 11 09:00 PM
GRAY WILLIAM GARRETT	Chief Financial Officer	Feb 06 '25	Sale	3.67	74,110	271,984	1,458,644	Feb 07 08:30 PM
Oliviero James F III	CEO, President and Director	Dec 18 '24	Sale	3.87	602,167	2,330,386	3,414,813	Dec 20 09:30 PM
Oliviero James F III	CEO, President and Director	Dec 19 '24	Sale	3.38	220,230	744,377	3,194,583	Dec 20 09:30 PM
GRAY WILLIAM GARRETT	Chief Financial Officer	Dec 18 '24	Sale	4.01	268,432	1,076,412	1,032,754	Dec 20 09:30 PM
Oliviero James F III	CEO, President and Director	Jun 26 '24	Sale	2.05	24,610	50,450	1,977,170	Jun 28 08:01 PM
GRAY WILLIAM GARRETT	Chief Financial Officer	Jun 26 '24	Sale	2.06	13,038	26,858	672,186	Jun 28 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CKPT

Checkpoint Therapeutics Inc

Upgrade your FINVIZ experience